116 related articles for article (PubMed ID: 11231620)
21. Use of the erythromycin breath test for in vivo assessments of cytochrome P4503A activity and dosage individualization.
Chiou WL; Jeong HY; Wu TC; Ma C
Clin Pharmacol Ther; 2001 Oct; 70(4):305-10. PubMed ID: 11673745
[No Abstract] [Full Text] [Related]
22. CAR/PXR provide directives for Cyp3a41 gene regulation differently from Cyp3a11.
Anakk S; Kalsotra A; Kikuta Y; Huang W; Zhang J; Staudinger JL; Moore DD; Strobel HW
Pharmacogenomics J; 2004; 4(2):91-101. PubMed ID: 14770174
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical localization and differential expression of cytochrome P450 3A27 in the gastrointestinal tract of rainbow trout.
Lee SJ; Hedstrom OR; Fischer K; Wang-Buhler JL; Sen A; Cok I; Buhler DR
Toxicol Appl Pharmacol; 2001 Dec; 177(2):94-102. PubMed ID: 11740908
[TBL] [Abstract][Full Text] [Related]
24. Effects of intracellular glutathione on sensitivity of Escherichia coli to mercury and arsenite.
Latinwo LM; Donald C; Ikediobi C; Silver S
Biochem Biophys Res Commun; 1998 Jan; 242(1):67-70. PubMed ID: 9439611
[TBL] [Abstract][Full Text] [Related]
25. Early postoperative erythromycin breath test correlates with hepatic cytochrome P4503A activity in liver transplant recipients.
Schmidt LE; Olsen AK; Stentoft K; Rasmussen A; Kirkegaard P; Dalhoff K
Clin Pharmacol Ther; 2001 Nov; 70(5):446-54. PubMed ID: 11719731
[TBL] [Abstract][Full Text] [Related]
26. Effects of antidepressant drugs on the activity of cytochrome P-450 measured by caffeine oxidation in rat liver microsomes.
Danie WA; Syrek M; Ryłko Z; Wójcikowski J
Pol J Pharmacol; 2001; 53(4):351-7. PubMed ID: 11990081
[TBL] [Abstract][Full Text] [Related]
27. Effects of pomegranate juice on human cytochrome p450 3A (CYP3A) and carbamazepine pharmacokinetics in rats.
Hidaka M; Okumura M; Fujita K; Ogikubo T; Yamasaki K; Iwakiri T; Setoguchi N; Arimori K
Drug Metab Dispos; 2005 May; 33(5):644-8. PubMed ID: 15673597
[TBL] [Abstract][Full Text] [Related]
28. Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques.
Kim JS; Nafziger AN; Tsunoda SM; Choo EE; Streetman DS; Kashuba AD; Kulawy RW; Beck DJ; Rocci ML; Wilkinson GR; Greenblatt DJ; Bertino JS
J Clin Pharmacol; 2002 Apr; 42(4):376-82. PubMed ID: 11936561
[TBL] [Abstract][Full Text] [Related]
29. Stereoselective metabolism of cisapride and enantiomer-enantiomer interaction in human cytochrome P450 enzymes: major role of CYP3A.
Desta Z; Soukhova N; Morocho AM; Flockhart DA
J Pharmacol Exp Ther; 2001 Aug; 298(2):508-20. PubMed ID: 11454912
[TBL] [Abstract][Full Text] [Related]
30. Selective induction of intestinal CYP3A23 by 1alpha,25-dihydroxyvitamin D3 in rats.
Xu Y; Iwanaga K; Zhou C; Cheesman MJ; Farin F; Thummel KE
Biochem Pharmacol; 2006 Jul; 72(3):385-92. PubMed ID: 16769037
[TBL] [Abstract][Full Text] [Related]
31. Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol.
Ushiama H; Echizen H; Nachi S; Ohnishi A
Clin Pharmacol Ther; 2002 Jul; 72(1):33-43. PubMed ID: 12152002
[TBL] [Abstract][Full Text] [Related]
32. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
Yasuda K; Lan LB; Sanglard D; Furuya K; Schuetz JD; Schuetz EG
J Pharmacol Exp Ther; 2002 Oct; 303(1):323-32. PubMed ID: 12235267
[TBL] [Abstract][Full Text] [Related]
33. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors.
Huang L; Wring SA; Woolley JL; Brouwer KR; Serabjit-Singh C; Polli JW
Drug Metab Dispos; 2001 May; 29(5):754-60. PubMed ID: 11302944
[TBL] [Abstract][Full Text] [Related]
34. Genetics of the variable expression of CYP3A in humans.
Wojnowski L
Ther Drug Monit; 2004 Apr; 26(2):192-9. PubMed ID: 15228164
[TBL] [Abstract][Full Text] [Related]
35. Prehepatic metabolism of drugs--a mechanism for low and variable oral bioavailability.
Hoppu K
Pediatr Nephrol; 1999 Jan; 13(1):85-9. PubMed ID: 10100297
[No Abstract] [Full Text] [Related]
36. Technology evaluation: MetXia-P450, Oxford Biomedica.
Hunt S
Curr Opin Mol Ther; 2001 Dec; 3(6):595-8. PubMed ID: 11804275
[TBL] [Abstract][Full Text] [Related]
37. Cytochrome P-450 and other determinants of pharmacokinetics, toxicity, and efficacy in humans.
Collins JM
Clin Cancer Res; 2000 Apr; 6(4):1203-4. PubMed ID: 10778942
[No Abstract] [Full Text] [Related]
38. Cytochrome P450 CYP3A5 in the human anterior pituitary gland.
Murray GI; Pritchard S; Melvin WT; Burke MD
FEBS Lett; 1995 May; 364(1):79-82. PubMed ID: 7750548
[TBL] [Abstract][Full Text] [Related]
39. Absence of CYP3A genetic polymorphism assessed by urinary excretion of 6 beta-hydroxycortisol in 102 healthy subjects on rifampicin.
Horsmans Y; Desager JP; Harvengt C
Pharmacol Toxicol; 1992 Oct; 71(4):258-61. PubMed ID: 1454750
[TBL] [Abstract][Full Text] [Related]
40. Phylogenetic analysis of the cytochrome P450 3 (CYP3) gene family.
McArthur AG; Hegelund T; Cox RL; Stegeman JJ; Liljenberg M; Olsson U; Sundberg P; Celander MC
J Mol Evol; 2003 Aug; 57(2):200-11. PubMed ID: 14562963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
